This funding supports studies aimed at overcoming methodological challenges in clinical trials of rapid-acting psychotropic interventional drugs (RAPIDs). It focuses on enhancing trial design rigor, improving data interpretability, and advancing understanding of optimal delivery and sustainability of RAPIDs and adjunctive psychosocial interventions to increase effectiveness and generalizability.
Eligible applicants include state, county, city, and tribal governments, for-profit and small businesses, public housing authorities, nonprofits, and institutions of higher education. Various types of organizations across the United States may apply.
